Floatz logo

Transcon Tlr7/8 Agonist

HPV-associated Cancers

Ascendis Pharma Oncology Division A/SPhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the HPV-associated Cancers cohort.

Asset / SponsorPhaseRating
Pembrolizumab
Ascendis Pharma Oncology Division A/S
Phase 1/2CCC
Cyclophosphamide
Ascendis Pharma Oncology Division A/S
Phase 1/2CCC
Epirubicin
Ascendis Pharma Oncology Division A/S
Phase 1/2CCC

Same molecule, other indications

Transcon Tlr7/8 Agonist is also rated in:

melanomaDormant
CCC
Indicative ·
48 / 100
View asset →
head and neck squamous cell carcinomaDormant
CCC
Indicative ·
48 / 100
View asset →
cervical cancerDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →